Ashland Signs Definitive Agreement to Sell Its Avoca Business to Mane
Ashland Inc. announced that it has signed a definitive agreement to sell its Avoca business to Mane. The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions.
Ashland’s Avoca business supplies the fixative Sclareolide and a range of contract manufacturing capabilities through two production facilities located in North Carolina and Wisconsin. The Avoca business line is the last entity formed following Ashland’s previous acquisition of Pharmachem.
Guillermo Novo, Chairman and CEO of Ashland, said: “The Avoca business is a strong player in the fixative space with a dedicated team and attractive manufacturing capabilities to meet customer needs. I would like to thank Avoca employees for their dedication and commitment to Ashland and our customers.”
Squire Patton Boggs served as legal counsel to Ashland.
You May Interested In
2026-07-24
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Ashland Advances $60 Million Strategic Manufacturing Network Optimization
-
Ashland Completes Sale of Its Avoca Business to Mane
-
Ashland Completes Sale of Its Avoca Business to Mane
-
Ashland sells nutraceutical business to Turnspire Capital Partners
-
Ashland Launches Perfectyl Biofunctional for Clear Skin, Utilizes GABA Amino Acid
-
Wanhua/Mitsubishi/Ashland Announced Price Increases Again, Up To 4400
-
Ashland will increase production capacity of hydroxyethyl cellulose at Nanjing plant
-
Mane launched two fresh coffee flavors to capture the fresh aroma
-
Ashland raw material ethylcellulose, won the PCHi Fountain Award
-
Ashland Shanghai Laboratory: Rosaliss can repair acne
Recommend Reading
-
“An €8 Billion Loss, Yet a 25% Price Hike”: Wacker Chemie’s Contradictory Crisis—Survival Move or Desperate Gamble?
-
“The C Empire Unites!”: Wanhua Chemical’s $26.5 Billion Bet on Ethylene Integration—Is It Becoming China’s BASF or the New Global Olefins Overlord?
-
Roche Takes Natco to Supreme Court Over Generic Risdiplam Launch in India
-
Bristol Myers Squibb Launches Mavacamten (“Kopozgo”) in India for Obstructive Hypertrophic Cardiomyopathy
-
Bayer’s Ambitious Gene & Cell Therapy Pipeline Eyes Parkinson’s, Oncology, Rare Diseases
-
Insufficient Support, Shandong Cyclohexanone Market in Decline
-
Weak and Stagnant Ethanol Market Conditions in China
-
Poor Demand Continues to Drive Down Butadiene Market
-
This week, the cyclohexane market in China mainly maintained stable operation (9.5-9.12)
-
Sodium Metabisulfite Prices Decline This Week in China (9.8-9.12)